vs
Side-by-side financial comparison of CASEYS GENERAL STORES INC (CASY) and Zoetis (ZTS). Click either name above to swap in a different company.
CASEYS GENERAL STORES INC is the larger business by last-quarter revenue ($4.5B vs $2.4B, roughly 1.9× Zoetis). Zoetis runs the higher net margin — 25.3% vs 4.6%, a 20.7% gap on every dollar of revenue. On growth, CASEYS GENERAL STORES INC posted the faster year-over-year revenue change (14.2% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $176.0M). Over the past eight quarters, CASEYS GENERAL STORES INC's revenue compounded faster (16.3% CAGR vs 4.4%).
Casey's Retail Company is a chain of convenience stores in the Midwestern and Southern United States. The company is headquartered in Ankeny, Iowa, a suburb of Des Moines. As of October 1, 2023, Casey's had 2,500 stores in 16 states. Following 7-Eleven's purchase of Speedway, Casey's is the third-largest convenience store chain in the United States and the largest that is wholly American-owned. It is one of two Iowa-based Fortune 500 companies. Casey's is famous for their pizza, including a b...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CASY vs ZTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $2.4B |
| Net Profit | $206.3M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 6.1% | 31.9% |
| Net Margin | 4.6% | 25.3% |
| Revenue YoY | 14.2% | 3.0% |
| Net Profit YoY | 14.0% | 3.8% |
| EPS (diluted) | $5.53 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.5B | $2.4B | ||
| Q3 25 | $4.6B | $2.4B | ||
| Q2 25 | $4.0B | $2.5B | ||
| Q1 25 | $3.9B | $2.2B | ||
| Q4 24 | $3.9B | $2.3B | ||
| Q3 24 | $4.1B | $2.4B | ||
| Q2 24 | $3.6B | $2.4B | ||
| Q1 24 | $3.3B | $2.2B |
| Q4 25 | $206.3M | $603.0M | ||
| Q3 25 | $215.4M | $721.0M | ||
| Q2 25 | $98.3M | $718.0M | ||
| Q1 25 | $87.1M | $631.0M | ||
| Q4 24 | $180.9M | $581.0M | ||
| Q3 24 | $180.2M | $682.0M | ||
| Q2 24 | $87.0M | $624.0M | ||
| Q1 24 | $86.9M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 6.1% | 31.9% | ||
| Q3 25 | 6.1% | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | 2.8% | 36.5% | ||
| Q4 24 | 6.1% | 31.6% | ||
| Q3 24 | 5.8% | 36.6% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | 3.4% | 34.1% |
| Q4 25 | 4.6% | 25.3% | ||
| Q3 25 | 4.7% | 30.0% | ||
| Q2 25 | 2.5% | 29.2% | ||
| Q1 25 | 2.2% | 28.4% | ||
| Q4 24 | 4.6% | 25.1% | ||
| Q3 24 | 4.4% | 28.6% | ||
| Q2 24 | 2.4% | 26.4% | ||
| Q1 24 | 2.6% | 27.4% |
| Q4 25 | $5.53 | $1.37 | ||
| Q3 25 | $5.77 | $1.63 | ||
| Q2 25 | $2.63 | $1.61 | ||
| Q1 25 | $2.33 | $1.41 | ||
| Q4 24 | $4.85 | $1.29 | ||
| Q3 24 | $4.83 | $1.50 | ||
| Q2 24 | $2.34 | $1.37 | ||
| Q1 24 | $2.33 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $492.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.8B | $3.3B |
| Total Assets | $8.6B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $492.0M | — | ||
| Q3 25 | $458.1M | $2.1B | ||
| Q2 25 | $326.7M | $1.4B | ||
| Q1 25 | $394.8M | $1.7B | ||
| Q4 24 | $351.7M | $2.0B | ||
| Q3 24 | $305.0M | $1.7B | ||
| Q2 24 | $206.5M | $1.6B | ||
| Q1 24 | $177.9M | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.8B | $3.3B | ||
| Q3 25 | $3.6B | $5.4B | ||
| Q2 25 | $3.5B | $5.0B | ||
| Q1 25 | $3.4B | $4.7B | ||
| Q4 24 | $3.3B | $4.8B | ||
| Q3 24 | $3.2B | $5.2B | ||
| Q2 24 | $3.0B | $5.0B | ||
| Q1 24 | $2.9B | $5.1B |
| Q4 25 | $8.6B | $15.5B | ||
| Q3 25 | $8.4B | $15.2B | ||
| Q2 25 | $8.2B | $14.5B | ||
| Q1 25 | $8.2B | $14.1B | ||
| Q4 24 | $7.7B | $14.2B | ||
| Q3 24 | $6.5B | $14.4B | ||
| Q2 24 | $6.3B | $14.2B | ||
| Q1 24 | $6.2B | $14.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $347.1M | $893.0M |
| Free Cash FlowOCF − Capex | $176.0M | $732.0M |
| FCF MarginFCF / Revenue | 3.9% | 30.7% |
| Capex IntensityCapex / Revenue | 3.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.68× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $682.2M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $347.1M | $893.0M | ||
| Q3 25 | $372.4M | $938.0M | ||
| Q2 25 | $333.9M | $486.0M | ||
| Q1 25 | $204.9M | $587.0M | ||
| Q4 24 | $270.7M | $905.0M | ||
| Q3 24 | $281.4M | $951.0M | ||
| Q2 24 | $288.4M | $502.0M | ||
| Q1 24 | $122.8M | $595.0M |
| Q4 25 | $176.0M | $732.0M | ||
| Q3 25 | $262.4M | $805.0M | ||
| Q2 25 | $153.1M | $308.0M | ||
| Q1 25 | $90.7M | $438.0M | ||
| Q4 24 | $160.0M | $689.0M | ||
| Q3 24 | $180.8M | $784.0M | ||
| Q2 24 | $92.1M | $370.0M | ||
| Q1 24 | $-27.0M | $455.0M |
| Q4 25 | 3.9% | 30.7% | ||
| Q3 25 | 5.7% | 33.5% | ||
| Q2 25 | 3.8% | 12.5% | ||
| Q1 25 | 2.3% | 19.7% | ||
| Q4 24 | 4.1% | 29.7% | ||
| Q3 24 | 4.4% | 32.8% | ||
| Q2 24 | 2.6% | 15.7% | ||
| Q1 24 | -0.8% | 20.8% |
| Q4 25 | 3.8% | 6.7% | ||
| Q3 25 | 2.4% | 5.5% | ||
| Q2 25 | 4.5% | 7.2% | ||
| Q1 25 | 2.9% | 6.7% | ||
| Q4 24 | 2.8% | 9.3% | ||
| Q3 24 | 2.5% | 7.0% | ||
| Q2 24 | 5.5% | 5.6% | ||
| Q1 24 | 4.5% | 6.4% |
| Q4 25 | 1.68× | 1.48× | ||
| Q3 25 | 1.73× | 1.30× | ||
| Q2 25 | 3.40× | 0.68× | ||
| Q1 25 | 2.35× | 0.93× | ||
| Q4 24 | 1.50× | 1.56× | ||
| Q3 24 | 1.56× | 1.39× | ||
| Q2 24 | 3.31× | 0.80× | ||
| Q1 24 | 1.41× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASY
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
